1. Home
  2. LITB vs NXTC Comparison

LITB vs NXTC Comparison

Compare LITB & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LightInTheBox Holding Co. Ltd.

LITB

LightInTheBox Holding Co. Ltd.

HOLD

Current Price

$2.87

Market Cap

48.8M

ML Signal

HOLD

Logo NextCure Inc.

NXTC

NextCure Inc.

HOLD

Current Price

$11.48

Market Cap

49.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LITB
NXTC
Founded
2007
2015
Country
Singapore
United States
Employees
N/A
N/A
Industry
Catalog/Specialty Distribution
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
48.8M
49.0M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
LITB
NXTC
Price
$2.87
$11.48
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$23.00
AVG Volume (30 Days)
15.1K
27.5K
Earning Date
11-12-2025
03-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.24
N/A
Revenue
$219,105,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$10.54
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.91
$2.69
52 Week High
$4.17
$15.74

Technical Indicators

Market Signals
Indicator
LITB
NXTC
Relative Strength Index (RSI) 60.98 43.94
Support Level $2.50 $10.42
Resistance Level $2.69 $12.48
Average True Range (ATR) 0.23 1.22
MACD -0.01 -0.25
Stochastic Oscillator 76.00 28.96

Price Performance

Historical Comparison
LITB
NXTC

About LITB LightInTheBox Holding Co. Ltd.

LightInTheBox Holding Co Ltd is an online retail company delivering products directly to consumers across the world. It provides apparel products including customized, special occasion and fast fashion apparel products; and other general merchandise products, such as accessories and gadgets, home and garden products, electronics and communication devices, and other products. The company operates in two segments: Product sales which consisted of online retailing of consumer products and sales to third-party sellers, and Services which consisted of provision of logistic services to companies and to individual customers. It derives maximum revenue from Product Sales. Geographically, it operates in Europe which is the key revenue driver, North America, and other countries.

About NXTC NextCure Inc.

NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.

Share on Social Networks: